AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PACS

Murray Jason Hulse sold $4.0M of PACS

Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 82,613 shares of PACS Group, Inc. (PACS) at an average of $48.42 ($47.55–$48.79, $4.00M total) across 3 trades over 2026-10-22 to 2026-10-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Murray Jason Hulse
Published Oct 26, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PACS
Bearish
medium confidence
Mentioned
$PACS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a negative signal by the market.

02

Market read

Primary insider sale filing; modest materiality for a small‑cap, likely limited price impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 7/10Timing: after-hours

Background

SEC Form 4 filing discloses an insider transaction by PACS Group's CEO.

Company-level read

Ticker impact

$PACSBearishMedium confidence
Context

CEO Murray Jason Hulse sold 82,613 shares for $4.0M via a 10b5-1 plan, reducing his stake to 54.2M shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $4M sale by the founder/CEO is material for a small‑cap, suggesting possible downside risk.

Market effects

Sector

Minimal impact on the broader healthcare services sector.

Regional

Limited to U.S. investors tracking PACS.

Global

Low; the filing is company‑specific.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing under a pre‑arranged plan, not a bearish signal.

Key entities

  • Company
    PACS Group, Inc.

    U.S. listed healthcare services provider.

  • Executive
    Murray Jason Hulse

    Co‑Founder, CEO & Chairman of PACS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PACS insider trading history →

Related articles

$PACSMedAI 8/10

What PACS Group (PACS) Said on Its Q3 Earnings Call

PACS Group reported 196 mature, 90 ramping, and 35 new skilled nursing facilities with occupancy ranging from 76.2% to 93.1%. The company acquired 32 Florida and 10 Texas skilled nursing operations post-quarter. PACS raised its 2026 revenue outlook to $5.95B-$6.05B and adjusted EBITDA to $685M-$695M, citing strength in existing operations and new acquisitions. Operating cash flow was $583.1M for the first nine months of 2026, with $707.4M in available liquidity.

finance.yahoo.com
$PACSHighAI 8/10

PACS Group Inc (PACS) (Q3 2026) Earnings Call Highlights: Revenue Tops

PACS Group Inc (NYSE:PACS) reported Q3 2026 revenue growth of 6.4%, with adjusted EBITDA up 33.6% to $175.7M. The company raised full-year guidance, citing strong occupancy and skilled mix improvements. PACS also highlighted a robust acquisition pipeline and integration plans for 31 Eduro facilities. Challenges include lower metrics at newly acquired facilities and ongoing government investigations.

finance.yahoo.com
$PACSHigh

Why is PACS stock surging today?

PACS Group Inc (PACS) stock rose 6.0% in after-hours trading after beating Q3 2026 earnings and revenue estimates. The company also raised its full-year 2026 Adjusted EBITDA and revenue guidance. Analysts maintain a 'Moderate Buy' rating with an average price target of $58.80. The surge was driven by company-specific news.

investing.com